Phase 2
Completed N=30
Meloxicam vs Placebo for Mobilization
Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma · Multiple Myeloma · Hematopoietic Stem Cells
Source: ClinicalTrials.gov NCT02003625 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: Numbers of Circulating CD34+ Cells on the First Day of Apheresis — 26; 30.7 Cells per microliter
Summary
This research study is evaluating a drug called meloxicam to see if it provides a benefit to people receiving Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
The participant is currently scheduled to receive an AHSCT, which is a procedure that removes blood-forming stem cells (cells from which all blood cells develop) from the body. These stem cells are stored and later given back to the participant by a process called apheresis. This is a standard procedure to treat certain blood diseases such as lymphoma and multiple myeloma. However the use of meloxicam with this procedure is considered investigational.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) which is given to decrease fever, swelling and pain that may come with inflammation. It has been approved by the FDA for the treatment of arthritis however it has not been approved for use in people receiving AHSCT.
This study will compare the combination of meloxicam with a drug called G-CSF (also called neupogen), to the combination of G-CSF with an agent that has no medicine (placebo). G-CSF is a substance that causes blood stem cells to change or increase in number when given to people undergoing AHSCT. The researchers would like to learn if giving meloxicam in combination with G-CSF to people before they undergo AHSCT will increase the number of stem cells available in the blood to collect and make the collection process easier.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Numbers of Circulating CD34+ Cells on the First Day of Apheresis |
26; 30.7 | — |
| PRIMARY Number of Apheresis Sessions Required to Collect ≥ 4 x 10^6 CD34+ Cells/kg for Multiple Myeloma Patients and ≥ 2 x 10^6 CD34+ Cells/kg for Lymphoma Patients |
4; 4; 6; 10; 4; 1 | — |
| PRIMARY Time to Neutrophil Engraftment After AHSCT |
10; 10 | — |
| PRIMARY Time to Platelet Engraftment After AHSCT |
18; 19 | — |
| SECONDARY Number of Patients With Grade 3+ Treatment Related Adverse Events |
0; 0 | — |
| SECONDARY Number of Participants That Received Red Blood Cell and Platelet Transfusions Prior to Engraftment |
14; 9; 6; 3 | — |
| SECONDARY Number of Patients That Failed to Achieve Stem Cell Mobilization. |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Participants must meet the following criteria on screening examination to be eligible to participate in the study:
- Patients with hematologic malignancies for whom autologous stem cell transplantation is deemed clinically appropriate. Patients participating in this study are patients who are going for their first attempt at stem cell mobilization.
- Non-Hodgkin's lymphoma, or Hodgkin's lymphoma: refractory/relapsed but chemosensitive disease. Patients with CR or PR will be eligible for this protocol.
The designation of PR requires all of the following:
- At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. These nodes or masses should be selected according to all of the following: they should be clearly measurable in at least 2 perpendicular dimensions; if possible they should be from disparate regions of the body; and they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.
- No increase should be observed in the size of other nodes, liver, or spleen.
- Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter.
- With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
- Bone marrow assessment is irrelevant for determination of a PR if the sample was positive before treatment. However, if positive, the cell type should be specified (eg, large-cell lymphoma or small neoplastic B cells). Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders. Multiple myeloma in first or second remission. Patients with CR or VGPR will be eligible for this protocol. [VGPR: Serum and urine M-protein detectable by immunofixation only but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level 2.0 mg/dl.
- Hepatic disease: SGOT or SGPT > 3 x normal; serum bilirubin >2.0 mg/dl that is not due to Gilbert's syndrome or hemolysis
- Uncontrolled infection.
- Pregnancy or lactation
- Patients with NSAIDs allergies, including patients who have experienced a prior GI bleed due to NSAIDs will be excluded. Patients who have had a recent GI bleed less than 2 weeks ago will be excluded. Patients who are on therapeutic dose anticoagulants will be excluded from this protocol.
Data sourced from ClinicalTrials.gov (NCT02003625). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.